CytRx Posts Higher Q3 Net Loss on Increased R&D Spending
CytRx reported this week a rise in its third-quarter net loss to $2.9 million, from $2.5 million in the year-ago quarter, largely as a result of an almost 125 percent increase in research and development spending to $1.5 million.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
